Systematic review and meta-analysis: Bezafibrate in patients with primary biliary cirrhosis

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 5407-5419

  Yin, Qin ^a,b   Li, Jingjing ^a   Xia, Yujing ^a   Zhang, Rong ^a,c   Wang, Jianrong ^a,c   Lu, Wenxia ^a,c   Zhou, Yuqing ^a,b   Zheng, Yuanyuan ^a   Abudumijiti, Huerxidan ^a   Chen, Rongxia ^a   Chen, Kan ^a   Li, Sainan ^a   Liu, Tong ^a   Wang, Fan ^a   Lu, Jie ^a   Zhou, Yingqun ^a   Guo, Chuanyong ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bezafibrate; Meta analysis; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BEZAFIBRATE; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN M; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; BLOOD; CHI SQUARE DISTRIBUTION; COMBINATION DRUG THERAPY; DRUG EFFECTS; LIVER; LIVER CIRRHOSIS, BILIARY; METABOLISM; ODDS RATIO; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

BEZAFIBRATE; BIOMARKERS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; ODDS RATIO; RISK FACTORS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84943643996     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S92041     Document Type: Article

References (42)

1. Prince MI, James OF. The epidemiology of primary biliary cirrhosis. Clin Liver Dis. 2003;7:795-819.
2. Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis (Review). Cochrane Database Syst Rev. 2012;12:CD000551.
3. Gong Y, Klingenberg SL, Gluud C. Systematic review and meta-analysis: D-Penicillamine vs placebo/no intervention in patients with primary biliary cirrhosis - Cochrane Hepato-Biliary Group. Aliment Pharmacol Ther. 2006;24(11-12):1535-1544.
4. Giljaca V, Poropat G, Stimac D, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2010;(5):CD004385.
5. Gong Y, Gluud C. Colchicine for primary biliary cirrhosis: a Cochrane Hepato-Biliary Group systematic review of randomized clinical trials. Am J Gastroenterol. 2005;100(8):1876-1885.
6. Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst Rev. 2007;(3):CD006000.
7. Gong Y, Christensen E, Gluud C. Cyclosporin A for primary biliary cirrhosis. Cochrane Database Syst Rev. 2007;(3):CD005526.
8. Zhang Y, Lu J, Dai W, et al. Combination therapy of ursodeoxycholic acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis. Gastroenterol Res Pract. 2013;2013:490731. doi:10.1155/2013/490731.
9. Zhang H, Yang J, Zhu R, et al. Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis. Drug Des Devel Ther. 2015;9:567-574.
10. Zhang Y, Li S, He L, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. Drug Des Devel Ther. 2015;9:2757-2566.
11. Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57(5):1931.
12. Zhang Y, Chen K, Dai W, et al. Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: a meta-analysis. Hepatol Res. 2015;45(1):48-58. doi:10.1111/hepr.12373. Epub 2014 Jul 28.
13. Iwasaki S, Ohira H, Nishiguchi S, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res. 2008;38(6):557.
14. Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2014;34(2):197-203. doi:10.1111/liv.12290. Epub 2013 Sep 2.
15. Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110(3):423-431. doi:10.1038/ajg.2015.20. Epub 2015 Mar 3.
16. Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol. 2010;44(5):371.
17. Takeuchi Y, Ikeda F, Fujioka S, et al. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol. 2011;26(9):1395-1401. doi:10.1111/j.1440-1746.2011.06737.x.
18. Itakura J, Izumi N, Nishimura Y, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res. 2004;29(4):216-222.
19. Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients. J Gastroenterol. 2003; 38(6):573-578.
20. Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000;95(1):326.
21. Akbar SM, Furukawa S, Nakanishi S, et al. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J Gastroenterol. 2005;40(2):157-163.
22. Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;1:CD009145. doi:10.1002/14651858.CD009145.pub2.
23. Kurihara T, Maeda A, Shigemoto M, et al. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol. 2002;97(1):212-214.
24. Gershwin ME, Ansari AA, Mackay IR, et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev. 2000;174:210-225.
25. Palmer JM, Kirby JA, Jones DE. The immunology of primary biliary cirrhosis: the end of the beginning? Clin Exp Immunol. 2002;129:191-197.
26. Tanaka A, Hirohara J, Nakanuma Y, et al. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. J Gastroenterol. 2015;50(6):675-682. doi:10.1007/s00535-014-0998-z. Epub 2014 Sep 20.
27. Takano K, Saeki C, Nakagawa R, et al. Long term prognosis and clinical features in patients with primary biliary cirrhosis. Hepatol Int. 2011; 5(2):607-624. doi:10.1007/s12072-015-9609-1.
28. Schulz KF, Chalmers L, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J Am Med Assoc. 1995; 273(5):408-412.
29. Chen K, Li J, Wang J, et al. 15-Deoxy-γ12,14-prostaglandin J2 reduces liver impairment in a model of ConA-induced acute hepatic inflammation by activation of PPARγ and reduction in NF-κB Activity. PPAR Res. 2014;2014:215631.
30. Cheng P, Chen K, Xia Y, et al. Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis. Drug Des Devel Ther. 2014;8:1277-1286. doi:10.2147/DDDT.S66573.
31. Shen M, Lu J, Dai W, et al. Ethyl pyruvate ameliorates hepatic ischemia-reperfusion injury by inhibiting intrinsic pathway of apoptosis and autophagy. Mediators Inflamm. 2013;2013:461536. doi:10.1155/2013/461536. Epub 2013 Dec 25.
32. Cheng P, Wang F, Chen K, et al. Hydrogen sulfide ameliorates ischemia/reperfusion-induced hepatitis by inhibiting apoptosis and autophagy pathways. Mediators Inflamm. 2014;2014:935251. doi:10.1155/2014/935251. Epub 2014 May 21.
33. Wang C, Chen K, Xia Y, et al. N-Acetylcysteine attenuates ischemia-reperfusion-induced apoptosis and autophagy in mouse liver via regulation of the ROS/JNK/Bcl-2 pathway. PLoS One. 2014;9(9):e108855. doi:10.1371/journal.pone.0108855.
34. Wang C, Xia Y, Zheng Y, et al. Protective effects of N-acetylcysteine in concanavalin A induced hepatitis in mice, induced hepatitis in mice. Mediators Inflamm. 2015;2015:189785.
35. Li J, Wang F, Xia Y, et al. Astaxanthin pretreatment attenuates hepatic ischemia reperfusion-induced apoptosis and autophagy via the ROS/MAPK pathway in mice. Marine Drugs. 2015;13(6):3368-3387.
36. Shen M, Chen K, Lu J, et al. Protective effect of astaxanthin on liver fibrosis through modulation of TGF-ß1 expression and autophagy. Mediators Inflamm. 2014;2014:954502. doi:10.1155/2014/954502. Epub 2014 Apr 17.
37. Dai W, Wang F, He L, et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor NFAT1. Mol Carcinog. 2015;54(4):301-311.
38. Dai W, Wang F, Lu J, et al. By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice. Oncotarget. 2015;6(15):13703-13717.
39. Jie L, Fan W, Weiqi D, et al. The hippo-yes association protein pathway in liver cancer. Gastroenterol Res Pract. 2013;2013:187070. doi:10.1155/2013/187070. Epub 2013 Aug 6.
40. Zhou Y, Dai W, Lin C, et al. Protective effects of necrostatin-1 in concanavalin A-induced acute hepatic injury in mice. Mediators Inflamm. 2013;2013:706156. doi:10.1155/2013/706156. Epub 2013 Oct 1.
41. Shen M, Lu J, Cheng P, et al. Ethyl pyruvate pretreatment attenuates concanavalin A-induced autoimmune hepatitis in mice. PLoS One. 2014;9(2):e87977. doi:10.1371/journal.pone.0087977.
42. Zhou Y, Chen K, He L, et al. The protective effect of resveratrol on concanavalin-A-induced acute hepatic injury in mice. Gastroenterol Res Pract. 2015;(2015):506390.